Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, those guys drove a few more nails in the coffin.
New article on DR70 for lung cancer.
DR-70 immunoassay and malignant pleural effusion
Beuy Joob and Viroj Wiwantikit
Additional article information
Sir,
The topic of DR-70 immunoassay and malignant pleural effusion (PE) is an interesting article in chest oncology.[1] In a study, Sengupta et al. reported that “DR-70 assay has high sensitivity in detecting underlying lung cancer, but has no role in differentiating malignant PE from non-malignant PE.”[1] There are many considerations on actual clinical use of DR-70 immunoassay. First, the diagnostic property of this assay is only fair[1,2] and there are several cancers (such as lung, stomach, breast and rectum cancers) that can induce abnormal results.[2] In addition, the significant high level can be seen in the cases with advanced disease, which means no usefulness for early detection.[3] Finally, there is still no report confirming the cost-effectiveness of this new test.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960827/?report=reader
Wolfie, your list of cancer diagnostic companies is WAY out of date.
Biocurex is still listed and they have not been in business for almost 2 years. A lender seized all lab equipment and they closed their doors at the end of 2012. In a few more months and they will get a revocation notice from the SEC. NO SEC filings since 2011.
Hint: keep looking at BioCurex on Bloomberg and you will probably begin to get old news from BioCurex on the Radient page.
From Mac's LinkedIn page:
"
Chairman & CEO
Radient Pharmaceuticals Corporation
Medical Devices industry
September 1992 – May 2014 (21 years 9 months) Tustin, California
Mrr. Maclellan resigned as Chairman and CEO to pursue other business interests in May 2014. In November 2008, Mr. MacLellan became Chairman & CEO of Radient Pharmaceuticals Corporation (formally AMDL, Inc.) which is currently listed on the OTCQX Exchange under the symbol (“RXPC”). From 1992 through October 2008 Mr. MacLellan held various independent positions on the Board of Directors including Chairperson of the Audit & Governance Committee's. RXPC is a in-vitro diagnostics biotech company with operations in Tustin California. Delivering cancer testing that matters through its Onko-Sure® in vitro diagnostic test that enables physicians and their patients to effectively monitor and/or detect solid tumor cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). Onko-Sure® is a simple, non-invasive blood test used for the detection and/or monitoring of 19 different types of cancers.(www.radient-pharma.com, www.onko-sure.com). '
Mac has removed any current connection with Radient.
Yes, those sites who still have Mac associated with Radient at WRONG.
End of your fantasy.
Wow, Wolfie doesn't even understand how "cookies" work. Bloomberg displays information on Provista because that is what Wolfie has been looking at.
That is my laugh of the day.
Wolfie, was that list supposed to be significant?
Is the fact that Radient is still on the list meaningful?
Dcspka, you obviously have not been paying enough attention to the Globalcancerdx website.
If Gartner was the head of the fantasy "takeover group", then why would the Aussies even have created the Radient-diagnostics website.
Why wouldn't your fantasy "takeover group" have surfaced by now? What would they be waiting for?
Are they going to wait for the Aussies to reorganize and void all their shares in a bankruptcy court? That wouldn't work out well would it?
This year, Gartner renewed his website for 5 years. I doubt that he would have done that if it was a temporary website.
Dcspka, on any go daddy website that is parked, go daddy will post a "do you want to buy this site". The site is not for sale but if you contact go daddy, they will attempt to contact the site owner to see if they want to sell the site. If they agree, Go Daddy will inflate the price to sell it back to you and make a profit in the process.
That's how it works.
There is no new patent attorney or patent agent.
This is what the USPT website states regarding the attorney/agent.
"No Attorney/Agent Data Found."
The previous agent petitioned the patent office to be removed as the patent agent.
She could no longer contact Radient.
Just like the Shanghai meat company, Radient has passed its expiration date.
"The study completed the requisite analyses and data evaluation needed to validate Provista's test, based on Radient Pharmaceutical Corporation's antigens for fibrinogen degradation products (FDP), successfully detects lung cancer with a high degree of accuracy."
Yes, LC Sentinel is just DR70. Thanks for posting the proof.
This is the LC Sentinel test. It tests for FDP just like Onko Sure.
"Radient has also begun rolling out a lung cancer screening kit called LC Sentinal in the US with partner, Provista Diagnostics. This kit was co-developed by the two companies and is based on the same technology as Onko-Sure."
It is not some fantasy "combination" test.
Wolfie, from the article you just posted.
Radient has also begun rolling out a lung cancer screening kit called LC Sentinal in the US with partner, Provista Diagnostics. This kit was co-developed by the two companies and is based on the same technology as Onko-Sure.
Wolfie, I am glad you finally admit that LC Sentinel is just made from Radients reagents.
Wolfie, read that press release carefully. It does not say Provista would use Provista reagents to create LC Sentinel, it says they will exclusively use reagents from Radient.
The only reagents radient had was for DR70.
There is no way anyone can spin that press release to say LC Sentinel is made from anything other than DR70.
Wolfie, look at the press release from Radient stating that LC Sentinel would use reagents from Radient.
"Gartner also expressed high praise for the quality of the RPC's manufacturing facilities and chemicals indicating the Company is pleased to be an exclusive partner of RPC in the development of the test. In conjunction with today's announcement, RPC and Provista also announced the two Companies will execute an exclusive lab partnership agreement where Provista Life Sciences will purchase RPC reagents exclusively for the development of LC Sentinel™."
http://www.marketwired.com/press-release/radient-pharmaceuticals-provista-life-sciences-announce-new-blood-test-lung-cancer-nyse-amex-rpc-1334094.htm
Companies drop prospective products from their pipelines all the time. LC Sentinel was something that Gartner liked but obviously Reese didn't.
Provista Life Science was split into two companies. Provistadx and the remaining products were for Alzheimer's which Gartner retained. Soon after Gartner was bumped from the CEO positon of Provistadx.
When Provista life science continued to delay the introduction of LC Sentinel, I called and spoke with the director of the lab. He said it was still undergoing testing. I asked more about the test and he said it measured FDP and was to be used specifically for Smokers and former smokers. He oould not give a date of introduction but estimated about 6 months.
Before the 6 months was up, ProvistaDX was created and LC Sentinel never showed up on their pipline any more.
DR70 and LC Sentinel are one in the same. The data and numbers are different because the use is different.
Wolfie, I have never said that Gartner and GCDx were associated with any fictitious "takeover" group you have fabricated.
ProvistaDX no longer wanted LC Sentinel and dropped it from their pipeline. They just gave it to Gartner to do what he wanted. I know it is really worthless and Reese decided it was worthless also.
If Gartner doesn't have "the lung cancer test", what was he hyping at the AZbio?
The fact is that Provistadx dropped LC Sentinel from their product line.
Gartner took the dropped test and hyped it on GCDx thinking he might suck up some investor dollars for his retirement.
It looks to me like Gartner is going to press forward with GCDx or at least that's what he has told some who have called him.
IMO, I think he will be able to get some fools to invest. Look at how many fools invested in Radient thinking Onko Sure had some value. It's a worthless test and so is the GCDx test but that doesn't stop people from being stupid.
Wolfie, the GCDx test has a huge false positive rate.
"87% sensitivity; 95% specificity"
That makes the test near worthless but when people like you who don't understand what 95% specificity really means, they fall all over themselves to throw money at the investment. That is what Gartner is banking on.
He just wants uninformed investors to fund his retirement.
Why can't Gartner get any money right now? He just has the concept of a business and nothing concrete. Get the website up, start offering tests, hype the result and fools will come running.
Gartner is just wondering how much of his own money he will have to spend to get the fools onboard.
Dcspak stated: "The majority of the world needs Onko-Sure because it is fast, very effective"
You have no idea at all about cancer testing.
Onko Sure has about 50 false positives for every cancer found. That is way, way too many and the reason why it has failed in the market place.
For example another study on a lung cancer screening test had 9 false positives for every cancer found. In their studies, 130 people were found with lung cancer and 1178 had false positive results. Of the 1178, 135 of those had serious complications from additional testing. Even at that false positive rate, it was questionable if endangering the lives of so many people with false positives was worth the advantages.
The following test study has a much better false positive specificity. It is 99% for a false negative and 99.8% for false positive.
"Simple blood test can detect lung cancer with high sensitivity and specificity - results from large clinical validation study published in the Journal of Clinical Oncology"
"We have developed a minimally invasive molecular diagnostic assay that quantifies the expression of specific miRNAs which are freely circulating in blood and indicate the presence of lung cancer," stated Gabriella Sozzi, Ph.D., Professor, Head of Cancer Genomics at INT. "Overall, the results of our study support the use of the assay as a tool to improve the early detection of lung cancer."
http://www.lef.org/news/LefDailyNews.htm?NewsID=21843&Section=Disease
Wolfie, your fantasy about the lenders, UNI, SRI, Gartner and Provista is just garbage.
The lenders do not hold any shares at all.
Look at the SEC filing in May 2012. The lenders gave Radient another $150,000 to pay the auditors so that the SEC filings could be brought up to date. Why? It clearly states that the lenders need the filings current so they could continue to sell shares under rule 144.
http://www.sec.gov/Archives/edgar/data/838879/000114420412030793/v313941_ex10-1.htm
If the lenders were converting and holding shares, they don't need current SEC filings. They were SELLING. End of story.
The UNI agreement is now cancelled because there is no longer any patent in force. UNI can do as they wish with DR70.
SRI never had any association with Radient. They were just selling the remaining DR70 kits that Umesh Bhatia had bought for the Indian farce.
Gartner can do whatever he wants with DR70. It is off patent.
Provista has denied any current connection with Radient and the only previous connection was made by Gartner when he was with Provista Life Sciences.
Your shares in Radient are worthless along with everyone who bought shares the lenders were selling.
Radient still has debts of almost $30 million dollars which makes its value as a shell zilch.
The Aussies now have the private company Radient Pharmaceuticals and can do whatever they want with it and no one will care. Not the SEC, no one but some sorry former shareholders.
Wolfie stated: "The number one cancer is LUNG CANCER..It totals all the combined and known cancers."
That is absolutely false. Lung cancer comprises 13.5% of all new cases of cancer per year.
Get your facts straight Wolfie.
http://seer.cancer.gov/statfacts/html/lungb.html
Dcspka, you obviously have never even thought about the math when you claim the debt owed to the lenders has been extinguished.
Here is the simple form of math for you.
From the SEC 10k:
On 15 Jun, 2012, there were 3.15 million shares remaining to be issued for the lenders to convert debt.
How do I know that? Outstanding shares on that date was 1.34 billion. The maximum shares that could be issued to the lenders was up to 4.5 billion. The remaining 500,000,000 (10% of the authorized shares) was in the employee benefit plan and cannot be issued to lenders.
The debt owed to the lenders per the 10K on 15 June, 2012 was $16.7 million. Additional debt was owed to others.
From 15 Jun, 2012 the share price rarely got above .0002 and most of the time was .0001 or less.
So, lets just ignore the fact that most of the shares remaining were converted at .0001 and use .0002 as the conversion price.
3.15 million shares remaining on 15 June, 2012 that could have been issued to the lenders, if converted at .0002 would have only given the lenders $630,000. The lenders got much less that that figure because the price per share was mostly .0001 and NOT .0002.
Now, please explain how the remaining $16.1 or more of debt was extinguished? With interest, that would be $24.8 million in debt still owed the lenders as of today. In addition, there is still other debt listed in the 10K that I have not even considered.
This totally blows your fantasy that there is no debt remaining.
Living, That doesn't look good for me getting all the points with my bet on no further communications. New website on the way but my guess would be just another site like the one for the Hong Kong test.
AMDL Diagnostics, Inc., was a subsidiary of Radient Pharmaceuticals, Inc. and went down the SEC tubes of revocation along with Radient.
It was a subsidiary of Radient pharmaceuticals. Claiming it still exists as a stand alone corp is just more false spin.
Originally, there was AMDL INC.
Then they acquired Jade pharmaceuticals as a subsidiary.
In 2009, AMDL created another subsidiary, AMDL Diagnostics, INC.
Later in 2009, they changed the name of AMDL, INC to Radient Pharmaceuticals, INC.
In 2010, they divested themselves of Jade Pharmaceuticals.
Just a note to add, during a conference call in 2008, it was announced that DR70 was going to be moved to a new subsidiary diagnostic division in order to spin it off for sale. AMDL wanted to be an exclusive Chinese Pharma.
Office Condominium Project Approved
An existing office building located at 2492 Walnut Avenue was approved to become office condominium
for sale office suites in the July 6th City Council meeting. Most of the building is currently being used for
Medical uses. The 11 office suites will vary in size from 7,500 to 16,543 square feet. There will be no
exterior changes. The project is close to the corner of Walnut Avenue and Tustin Ranch Road.
How will you change the spin if and when Gartner begins to sell his lung cancer test and no license is granted? There would not have ever been any reason for Gartner to have owned any shares in Radient.
Dcspka,
There is a good reason why Gartner was not selling his lung cancer test. Prior to last month, he would have needed to pay Radient a license fee and royalties. Today, there is no need at all to pay Radient any fees at all. Radient's patent expired last month.
Gartner no longer has any need for any agreement with Radient.
I still do not think Gartner has found any significant investors but if he in fact begins to sell lung cancer tests, his chances of obtaining money increases greatly.
Why do I think they are looking for investors? Look at the comment by Jimtash where someone at GCDX looked at his linkedin page to see if he would possibly be an investor.
Gartner is now current with his hosting fees but the website is parked awaiting action by Gartner.
RADIENT PHARMACEUTICALS Corp (Filer) CIK: 0000838879 S-3 filing 333-172124
xxxxxx to cfletters Feb 22 2011
Dear Sirs:
Radient Pharmaceuticals has recently filed an abreviated registration form S3. Per SEC rules, they are not allowed to use an S3 because of previous defaults upon notes in the past year.
Quote from the Q3 2010 financial report:
Defaults on Senior Notes and Proposed Debt Exchanges
The Company did not pay the interest due on the Series 1 Senior Notes or the Series 2 Senior Notes (together “the Series 1 and 2 Notes”) due on December 1, 2009 or March 1, 2010. The Company did not have sufficient cash to satisfy these debts and carry on current operations. Consequently, under the terms of the Series 1 and 2 Notes, the interest rate increased from 12% to 18% per annum. The failure to pay interest as scheduled represented an event of default under the terms of the Notes and all senior debt was classified as current. However, none of the holders declared default, or declared the outstanding Series 1 and 2 Notes and other contractual obligations immediately due.
http://sec.gov/Archives/edgar/data/838879/000114420410062890/v203402_10q.htm
From the SEC form S3 eligibility:
5. Neither the registrant nor any of its consolidated or unconsolidated subsidiaries have, since the end of the last fiscal year for which certified financial statements of the registrant and its consolidated subsidiaries were included in a report filed pursuant to Section 13(a) or 15(d) of the Exchange Act: (a) failed to pay any dividend or sinking fund installment on preferred stock; or (b) defaulted (i) on any installment or installments on indebtedness for borrowed money, or (ii) on any rental on one or more long term leases, which defaults in the aggregate are material to the financial position of the registrant and its consolidated and unconsolidated subsidiaries, taken as a whole.
http://www.sec.gov/about/forms/forms-3.pdf
From the next 10k filing:
" On March 10, 2011, the Company received notice from the SEC that it did not meet the eligibility requirements for the S-3 filing to register the shares on such form and therefore must seek to register the shares on Form S-1."
Dcspka stated: ""Question: what is the real value/financial leverage RXPC has with Onko-Sure/DR-70 at this point in time? Any left?"
When the last patent expired, it then made all the value equal between Radient, UNI and GCDx. All of them have the technology and knowhow to manufacture DR70 and no one pays any royalty to anyone.
The Aussies now also have the technology so you might also put them on an equal level with UNI and GCDx.
As for CIT which you now claim has all the value, please explain why Radient stated the following:
"Due to the following conditions at December 31, 2010, we decided to impair the remaining balance of our CIT asset:
· Lack of any potential future revenue;
· Lack of future cash flows;
· High cost of future clinical studies; and
· Limited time remaining on the patent. "
Dcspka, you cannot just take the Radient shell and reverse merge a company into it. Radient has 5 billion shares. That's a nightmare to deal with. You would have to get rid of those former shareholders. As for the $30 million in debt, you would have to deal with that also.
The Aussies would have to take Radient into chapter 11 and void all the shares but that still does not take care of the lenders. That is a lot of debt but if it is as you and some others claim that the lenders have taken shares, the Aussies can wipe them out the same as the other shareholders. That would be the perfect situation for the Aussies but lets not kid ourselves, the lenders would certainly not be dumb enough to own shares in Radient. That was just all a Wolfie dream.
With all the debt, 5 billion shares and being a stale corporation for over 3 years, it just does not have much value. How do you come up with financial data for the past 3 years. Everyone is gone. It would just be a financial nightmare.
IMO, you have heard the last from Radient. The Aussies just wanted what assets were left.
Jimtash, GCDx is still looking for money. If you thought Onko Sure had value, then you might want to become a shareholder there. I still don't think it has enough value as a dx to get FDA approval and be a success but it is a ton better shot than Radient.
The company listing Jim Green as the chairman at that location is under a stop order from the Australian government.
It is another fraud. ECSI limited.
http://www.investogain.com.au/company/ecsi-limited
This whole Aussie group appears to be a bunch of criminals.
Jim Green was listed as chairman for a company in the same building as Darren Brown of on line Capital.
That is the connection the Aussies had with Jim Green.
http://www.ivycorporatecentre.com.au/tenants.aspx
MacLellan has quickly updated his linkedin page to remove his association with Radient.
Douglas MacLellan's Overview
Current Chairman of the Board at eWellness Healthcare Corporation
Co-Founder & Chairman of the Board at InnoVare Products, Inc
Director & Chairman of the Audit and Compensation Committees at China Net Online Holdings, Inc.
Chairman & CEO at The MacLellan Group
see less
Past Chairman & CEO at Radient Pharmaceuticals Corporation
Chairman of the Board at NewsGrade Corporation
Vice Chairman at Ocean Smart, Inc.
Looks like all the subjects on the board died at one time.
The patent died.
The patent agent is gone.
The stock is revoked.
GCDx is not even paying their website bills.
Radient's old building is being converted in office condos.
And the Aussies have apparently gone into hiding.